AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength - AbbVie (NYSE:ABBV)

AbbVie's (ABBV) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued an "overweight" rating and set a $240.00 price target on shares of AbbVie in a report on Thursday.

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

The post Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy appeared first on 24/7 Wall St.. Quick Read AbbVie (ABBV) reported Q1 revenue of $15B, beating consensus by $280M, while Skyrizi surged 30.9% YoY to $4.48B and Rinvoq grew 23.3% to $2.12B. Management raised full-year adjusted EPS guidance to $14.08-$14.28, and the company’s migraine franchise posted strong growth with Qulipta up 53.6% and Ubrelvy up 41.4%. AbbVie…

AbbVie signals $14.08-$14.28 2026 adjusted EPS as Skyrizi and Rinvoq outlook rises (NYSE:ABBV)

AbbVie (ABBV) Q1 2026 earnings call recap: guidance raise, $15B revenue, Skyrizi/Rinvoq outlook, pipeline catalysts & risks—read key takeaways now.

AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength - AbbVie (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) on Wednesday reported first-quarter 2026 sales of $15.00 billion, beating the consensus of $14.72 billion. AbbVie Q1 Revenue Beats Driven By Immunology Growth Sales increased 12.4% on a reported basis or 10.3% on an operational basis. The company reported adjusted earnings of $2.65 per share, up 7.7%, beating the consensus of $2.59. Global net revenues from the immunology portfolio were $7.29 billion, up 16.4% (+14.3% on …

AbbVie beats Q1 2026 earnings, raises full-year forecast

Skyrizi and Rinvoq together generated more than $6.6 billion in quarterly sales, far outpacing Humira's $688 million

AbbVie Inc. (NYSE:ABBV) Q1 2026 Earnings Call Transcript

Operator: Good morning, and thank you for standing by. Welcome to the AbbVie First Quarter 2026 Earnings Conference Call. [Operator Instructions] Today's call is also being recorded.